BIOMAT Database Logo BIOMAT Database Logo

Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. 2010

Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Department of Surgery II, Faculty of Medicine, University of Miyazaki, Kihara 5200, Kiyotake, Miyazaki, 889-1692, Japan. mtomita@med.miyazaki-u.ac.jp

BACKGROUND Prognostic impact of tumour marker index (TMI) based on preoperative serum carcinoembryonic antigen (CEA) and CYFRA 21-1 in non-small cell lung cancer (NSCLC) was examined using patients with a follow-up period more than 5 years. METHODS Two hundred and ninety-three consecutive NSCLC patients were reviewed retrospectively, and any patients with follow-up periods less than 5 years were omitted. RESULTS The 5-year survival of the patients with normal and high serum CEA levels was 71.52% and 48.41%, respectively (p<0.0001). The 5-year survival of the patients with a high serum CYFRA 21-1 level was 39.66%, which was significantly poorer compared with that of the patients with a normal serum CYFRA 21-1 level (66.95%, p<0.0001). There was a 5-year-survival rate of 72.28% in patients with a TMI less than or equal to 1.0 compared to only 37.08% in patients with a TMI greater than 1.0 (p<0.0001). Both univariate and multivariate analyses indicated the independent prognostic impact of TMI. CONCLUSIONS TMI may be useful for predicting the prognosis of NSCLC patients.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
January 1998, Anticancer research,
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.
October 2011, Lung cancer (Amsterdam, Netherlands),
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
[Cyfra 21-1 new marker for non-small cell lung cancer].
January 1994, Pneumonologia i alergologia polska,
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
January 1999, Anticancer research,
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score.
January 2008, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
April 2004, Respiratory medicine,
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
October 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Evaluation of CYFRA 21-1 as a new marker for non-small cell lung cancer.
March 1994, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP),
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
April 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Masaki Tomita, and Tetsuya Shimizu, and Takanori Ayabe, and Akihiro Yonei, and Toshio Onitsuka
Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
July 1995, Chest,
Copied contents to your clipboard!